The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Path: Pneumocyte atypia (reactive epithelial cells) (a.k.a. the "Napoleon Hat" sign)
Publications
Drug-induced lung disease: a pragmatic classification incorporating HRCT appearances.
Seminars in respiratory and critical care medicine 2003 Aug;24;445-54 — 2003 Aug — 445-54
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 25-1997. A 60-year-old man with pulmonary infiltrates after a bone marrow transplantation.
The New England journal of medicine 1997 Aug 14;337;480-9 — 1997 Aug 14 — 480-9
Pulmonary lesions associated with busulfan therapy of chronic myelogenous leukemia.
Cancer 1971 May;27;1074-80 — 1971 May — 1074-80
Busulphan lung.
Thorax 1968 Mar;23;187-93 — 1968 Mar — 187-93
Busulfan lung. Report of two cases and review of the literature.
The American journal of roentgenology, radium therapy, and nuclear medicine 1974 Jan;120;151-6 — 1974 Jan — 151-6
Interstitial pulmonary fibrosis, atypical epithelial changes and bronchiolar cell carcinoma following busulfan therapy.
Cancer 1968 Nov;22;1027-32 — 1968 Nov — 1027-32